🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07768475
Active, not recruiting Not applicable

A Prospective Study Comparing Visual Outcomes and Patient Satisfaction Following Implantation of the Clareon PanOptix Versus Tecnis Odyssey IOL in Patients Undergoing Cataract Surgery.

NCT07768475 · tracked via the Priya Life Science USA tracker
Sponsor
Nvision Laser Eye Centers
Phase
Not applicable
Started
2025-07-07
Last updated
2026-08-17

Condition(s) studied

Cataracts

Investigational drug(s) / intervention(s)

Intraocular Lens ImplantIntraocular Lens Implant

Intraocular Lens Implant: Clareon® PanOptix® IOL models CNWTT0 and CNWTTx, x=3 \& 4 (BLF)

Intraocular Lens Implant: Tecnis® Odyssey® IOL models DRN00V, DRT150, DRT225

Study summary

To evaluate visual outcomes and patient satisfaction following bilateral implantation of the Clareon PanOptix versus Tecnis Odyssey IOL in patients undergoing cataract surgery

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Willing and able to understand and sign informed consent 2. Willing and able to participate with all study testing 3. Adult patient diagnosed with age-related cataracts bilaterally 4. Planned bilateral cataract removal by phacoemulsification with bilateral implantation of the Clareon PanOptix/ Clareon PanOptix Toric or Tecnis Odyssey IOL/ Tecnis Odyssey IOL Toric (T3/4 or DRT150, DRT225) 5. Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively as determined by surgeon 6. Residual astigmatism expected to be ≤ 0.50 diopters in both eyes postoperatively as determined by surgeon (After using either toric IOL or arcuate incision with laser) 7. Normal ocular findings aside from cataract Exclusion Criteria: 1. HOA greater than 0.4 μm within central 4 mm 2. Corneal dystrophies, degenerations, irregular astigmatism or any corneal abnormality aside from regular astigmatism deemed to be of clinical significance by the surgeon. 3. Any pathologic conditions that might affect ease of cataract removal (pseudoexfoliation, posterior polar, etc) as determined by surgeon 4. Strabismus with or without amblyopia in either eye 5. Previous history of any ocular surgery including corneal refractive surgery 6. Presence of any macular disease, history of retinal detachment, or posterior segment abnormality deemed to be of clinical significance by the surgeon. 7. Presence of glaucoma 8. Presence of any acute or chronic systemic disease that would confound the results of this study as determined by the surgeon (e.g. uncontrolled diabetes, immunocompromise, autoimmune disease, etc). 9. Any planned simultaneous/combined procedures at time of cataract surgery (e.g. MIGs). 10. Any subjects with intraoperative complications, including vitreous loss, posterior capsular rupture, zonular dialysis, decentered or tilted IOL, diffuse corneal epithelial defect, and use of iris hooks or expanders, will be excluded from analysis.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Hyperspeed LASIK Rowland Heights California
Seeta Eye Center Poughkeepsie New York
Texas Eye and Laser Center Hurst Texas
Parkhurst Nuvision San Antonio Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07768475 on ClinicalTrials.gov ↗ ← All trials in the USA